IN BRIEF: Hemogenyx Nets Financing Facility Of Up To GBP60 Million

Wed, 18th Nov 2020 20:22

Hemogenyx Pharmaceuticals PLC - pre-clinical stage biopharmaceutical firm headquartered in London - Enters into convertible loan note financing facility with Mint Capital Ltd to which it has conditionally agreed to issue up to GBP60 million convertible unsecured loan notes to Mint Capital. Funds will allow Hemogenyx to accelerate and broaden development pipeline of novel therapies and treatments for blood cancers and viral diseases.

Current stock price: 9.28 pence

Year-to-date change: up sharply from 1.95p

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Related Shares

More News

25 Apr 2024 12:19

EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately report...

29 Feb 2024 14:04

Hemogenyx Pharmaceuticals raises money for leukaemia treatment

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said it has raised GBP3.3 million through a placing.

16 Feb 2024 11:27

Hemogenyx shares rise on potential for CBR to treat brain diseases

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said research has shown that its proprietary chimeric bait receptor can be delivered into th...

14 Feb 2024 10:14

Hemogenyx says CBR can be used intranasally to treat viral infections

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said its chimeric bait receptor can be delivered intranasally in the form of messenger RN...

9 Feb 2024 10:00

IN BRIEF: Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - US Food & Drug Administration...